![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
Van kleine vlogs tot grote bedrijfsfilms: video’s zijn voor bedrijven en merken een middel om de naamsbekendheid te vergroten en nieuwe mensen te bereiken. Een belangrijk onderdeel om mee te nemen in de marketing- en...
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial
Regulatory filings expected in first half of 2020
Novartis announce robust Phase 3 trials for ofatumumab in MS
Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the risk of progression by 30% compared to Sanofi’s Aubagio. The drug, a once...
Amgen’s Kyprolis + Darzalex combo shows progression-free survival benefit in mutiple myeloma
Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the steroid dexamethasone, showing that the combo met its primary endpoint of progression-free...
Aspen’s drug to prevent preterm birth approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Aspen Pharmacare’s hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women, the South African drugmaker’s CEO...
Ardelyx’s Ibsrela wins FDA approval for IBS-C
Ardelyx announced that it has received FDA approval for its NHE3 sodium transport inhibitor Isbrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Isbrela is a 50mg, twice...
Aimmune gets FDA panel backing for peanut allergy therapy
Step closer to becoming first approved treatment
Is jouw nieuwe digitale propositie bij voorbaat gedoemd tot mislukken?
De digitale transformatie is in volle gang. Big data, machine learning, AI, VR. Je wilt graag een voorsprong pakken met deze tech-trends. Maar hoe? Als marketeers lanceren we geregeld nieuwe digitale proposities. Helaas...
How marketers can shape customer sentiment during events
Marketers’ ability to influence user-generated content surrounding customers’ brand or firm-related interactions, and its sentiment in particular, may be an un-tapped use of social media in marketing.
Insulin drug could treat glioblastoma
A research team from the University of Georgia’s Regenerative Bioscience Center has found that a compound molecule used for drug delivery of insulin could be used to treat glioblastoma, an aggressive, usually...
How to Create a Better Distribution Plan to Get Your Content Seen
Your content marketing success often lives or dies by your distribution and promotion choices. Set the stage for optimal content discovery, engagement, and performance with this handy tutorial on the essentials and...
Discover the Secrets to Successful Content Creation
An outsider might think content creation is easy. But we all know there’s a lot more to it. Discover the secrets of producing well-conceived, well-written stories that deliver for your audience and your brand with this...
Merck takes evobrutinib for MS into phase 3, on mixed data
First drug in class to reach this stage for the illness
Xeris Pharma’s low blood sugar treatment wins FDA approval
The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc’s glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.
Latest Winners of Content Marketing Awards Up the Game
See the innovative, strategic, and creative content coming from our industry. Check out the newly announced winners of the 2019 Content Marketing Awards. Plus, go behind the scenes and the results for the Project of the...
[column] MarketingTroonrede: ‘Wake-up call en inspiratiebron tegelijkertijd’
Tijdens de MarketingTroonrede 2018 was ik onder de indruk van de passie van zowel de sprekers als het publiek. De inspirerende troonrede ‘Menselijke maat in disruptieve tijden’, uitgesproken door Rob Beltman, deed een...
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment of newly diagnosed glioblastoma multiforme (GBM) when combined with the...
Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial
The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran, an investigational twice-yearly cholesterol-lowering therapy. Inclisiran is a...
